BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Resminostat Hits Endpoint in Hodgkin's Lymphoma Trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Resminostat Hits Endpoint in Hodgkin's Lymphoma Trial
Sep. 7, 2011
By
Cormac Sheridan
No Comments
4SC AG's histone deacetylase (HDAC) inhibitor resminostat attained the primary endpoint of a Phase II trial in patients with relapsed or refractory Hodgkin's lymphoma (HL).
BioWorld